Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fagan

Showing results (311-320 of 489) with videos related to

Pageof 49
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 5, 2018
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imagingSuzanne E Schindler, Julia D Gray, Brian A Gordon, et al.
Scientific Reports|July 7, 2016
Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's diseaseJulia Muenchhoff, Anne Poljak, Anbupalam Thalamuthu, et al.
Neurology|March 25, 2016
Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children StudyChengjie Xiong, Mateusz S Jasielec, Hua Weng, et al.
Plos One|February 25, 2011
Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's diseaseJohn S K Kauwe, Carlos Cruchaga, Celeste M Karch, et al.
JAMA Neurology|September 15, 2015
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer DiseaseMaartje I Kester, Charlotte E Teunissen, Daniel L Crimmins, et al.
Brain : a Journal of Neurology|March 27, 2018
Data-driven models of dominantly-inherited Alzheimer's disease progressionNeil P Oxtoby, Alexandra L Young, David M Cash, et al.
Human Molecular Genetics|July 24, 2012
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's diseaseCarlos Cruchaga, John S K Kauwe, Petra Nowotny, et al.
JAMA Neurology|January 8, 2019
Assessment of Racial Disparities in Biomarkers for Alzheimer DiseaseJohn C Morris, Suzanne E Schindler, Lena M McCue, et al.
BMJ Open|September 16, 2021
Falls: a marker of preclinical Alzheimer disease: a cohort study protocolRebecca M Bollinger, Audrey Keleman, Regina Thompson, et al.
Molecular Neurodegeneration|April 14, 2007
Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphismsSuzanne E Wahrle, Aarti R Shah, Anne M Fagan, et al.
Pageof 49

Showing results (311-320 of 489) with videos related to

Sort By:
Pageof 49
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 5, 2018
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imagingSuzanne E Schindler, Julia D Gray, Brian A Gordon, et al.
Scientific Reports|July 7, 2016
Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's diseaseJulia Muenchhoff, Anne Poljak, Anbupalam Thalamuthu, et al.
Neurology|March 25, 2016
Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children StudyChengjie Xiong, Mateusz S Jasielec, Hua Weng, et al.
Plos One|February 25, 2011
Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's diseaseJohn S K Kauwe, Carlos Cruchaga, Celeste M Karch, et al.
JAMA Neurology|September 15, 2015
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer DiseaseMaartje I Kester, Charlotte E Teunissen, Daniel L Crimmins, et al.
Brain : a Journal of Neurology|March 27, 2018
Data-driven models of dominantly-inherited Alzheimer's disease progressionNeil P Oxtoby, Alexandra L Young, David M Cash, et al.
Human Molecular Genetics|July 24, 2012
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's diseaseCarlos Cruchaga, John S K Kauwe, Petra Nowotny, et al.
JAMA Neurology|January 8, 2019
Assessment of Racial Disparities in Biomarkers for Alzheimer DiseaseJohn C Morris, Suzanne E Schindler, Lena M McCue, et al.
BMJ Open|September 16, 2021
Falls: a marker of preclinical Alzheimer disease: a cohort study protocolRebecca M Bollinger, Audrey Keleman, Regina Thompson, et al.
Molecular Neurodegeneration|April 14, 2007
Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphismsSuzanne E Wahrle, Aarti R Shah, Anne M Fagan, et al.
Pageof 49